Pyxis Oncology(PYXS) - 2024 Q2 - Quarterly Results

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., August 14, 2024 – Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat can ...